Raptor Pharmaceutical Corp. to Present at the Lazard Capital Markets 9th Annual Healthcare Conference 2012

        Print
| Source: Raptor Pharmaceutical Corp.

NOVATO, Calif., Nov. 9, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that Julie Anne Smith, Executive Vice President, Strategy and Chief Operating Officer of Raptor, will present an overview of the Company at the Lazard Capital Markets 9th Annual Healthcare Conference in New York, NY at The Pierre hotel. Raptor's presentation will take place on Wednesday, November 14, 2012 beginning at 9:30 a.m. ET.

A live audio webcast and 14-day archive of the Lazard presentation will be available at http://ir.raptorpharma.com/events.cfm

About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical Corp. ("Raptor") (Nasdaq:RPTP) seeks to research, develop, and provide access to medicines that improve life for patients with severe and rare disorders. Raptor currently has product candidates in clinical development designed to potentially treat nephropathic cystinosis, non-alcoholic steatohepatitis, Huntington's Disease, and aldehyde dehydrogenase deficiency.

Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein and related proteins that are designed to target cancer and infectious diseases.

For additional information, please visit www.raptorpharma.com.

The Raptor Pharmaceutical Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7180

Trout Group (investors)
Lauren Glaser
(646) 378-2972


EVC Group (media)
Janine McCargo
(646) 688-0425